# Nuvation Bio

Type: Company (NUVB)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/nuvation-bio
Canonical HTML page: https://getfinancebrief.com/entity/nuvation-bio

## Timeline

- **2026-09-06**: Coverage Highlights Market Divergence — Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.
- **2026-09-03**: Cramer Calls NUVB 'Pure Speculation' — On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.
- **2026-08**: FDA Grants Fast Track Designation to Safusidenib — Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.

## Recent coverage (1 stories)

### Cramer's 5-Word NUVB Warning as Biotech Surges: 2026 Net Loss Expected
2026-09-07 19:39:28 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Jim Cramer's September 3 'pure speculation' call on Nuvation Bio hits at a moment of momentum: shares rose on FDA Fast Track news and strong early IBTROZI adoption. Yet analysts forecast a full-year 2026 net loss, making the rally a contest between pipeline optionality and burn rate.
Full story: https://getfinancebrief.com/story/nuvation-bio-cramer-pure-spec-net-loss-valuation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.